Merck oncology VPs Gregory Lubiniecki (L) and Scot Ebbinghaus
September 7, 2022 06:05 PM EDT
R&D

#ES­MO22: Out­side liv­er can­cer, Keytru­da notch­es key win in neoad­ju­vant set­ting but flops in head and neck tu­mors

Paul Schloesser

Associate Editor

ES­MO in Paris is just get­ting start­ed, and ex­clud­ing a promi­nent miss in liv­er can­cer, Mer­ck is kick­ing things off with two ad­di­tion­al swings …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times